Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Accenture
US Department of Justice
Colorcon
Novartis
Medtronic
Cipla
Daiichi Sankyo
Merck
AstraZeneca

Generated: August 19, 2017

DrugPatentWatch Database Preview

KYPROLIS Drug Profile

« Back to Dashboard

Which patents cover Kyprolis, and what generic Kyprolis alternatives are available?

Kyprolis is a drug marketed by Onyx Therap and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-four patent family members in thirty-five countries.

The generic ingredient in KYPROLIS is carfilzomib. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.

Summary for Tradename: KYPROLIS

Patents:11
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list32
Clinical Trials: see list48
Patent Applications: see list138
Drug Prices:see details
DailyMed Link:KYPROLIS at DailyMed

Pharmacology for Tradename: KYPROLIS

Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Onyx Therap
KYPROLIS
carfilzomib
POWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: KYPROLIS

Drugname Dosage Strength RLD Submissiondate
carfilzomibFor Injection60 mg/vialKyprolis7/20/2016

Non-Orange Book Patents for Tradename: KYPROLIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,198,270Compounds for proteasome enzyme inhibition► Subscribe
8,324,174Compounds for enzyme inhibition► Subscribe
8,207,124Compounds for enzyme inhibition► Subscribe
8,088,741Compounds for enzyme inhibition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KYPROLIS

Country Document Number Estimated Expiration
Japan6081964► Subscribe
Japan4990155► Subscribe
Singapore185963► Subscribe
South Korea20150004797► Subscribe
Israel183607► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: KYPROLIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
015Luxembourg► SubscribePRODUCT NAME: CARFILZOMIB EVENTUELLEMENT SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151123
2016 00014Denmark► SubscribePRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1060 20151123
C0017France► SubscribePRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123
0160008 00189Estonia► SubscribePRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015
90013-6Sweden► SubscribePRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Chubb
Fish and Richardson
Colorcon
Johnson and Johnson
Merck
Daiichi Sankyo
Federal Trade Commission
Julphar
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot